P. Watkins

发表

Explorer Refining Liver Safety Risk Assessment

T. Parry, J. Iaci, A. Eisen, 2017 .

Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters

C. Battista, J. Woodhead, B. Howell, 2017, Clinical pharmacology and therapeutics.

Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials

S. Siler, T. Parry, B. Howell, 2017, Clinical pharmacology and therapeutics.

Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug‐Induced Liver Injury

Y. Yang, D. Longo, B. Howell, 2016, CPT: pharmacometrics & systems pharmacology.

Insulin control of glucose metabolism in man: a new kinetic analysis.

M Berman, P A Insel, P. Insel, 1975, The Journal of clinical investigation.

Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury

M. Molokhia, E. Bjornsson, P. Watkins, 2011, Clinical pharmacology and therapeutics.

Drug Safety Sciences and the Bottleneck in Drug Development

P B Watkins, P. Watkins, 2011, Clinical pharmacology and therapeutics.

Use of Pharmaco‐Metabonomics for Early Prediction of Acetaminophen‐Induced Hepatotoxicity in Humans

F. Wright, P. Watkins, J. Winnike, 2010, Clinical pharmacology and therapeutics.

Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management

M. Mosedale, P. Watkins, Paul B. Watkins, 2017, Clinical pharmacology and therapeutics.

Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen

P. Bushel, P. Watkins, R. Paules, 2016, Clinical pharmacology and therapeutics.